Skip to content
Medical Health Aged Care

QPS Launches New Leukopak and Cell Therapy Products Facility

QPS Holdings, LLC 3 mins read

Clinical Research Supports Economic Growth and Development, While Making a Global Difference


SPRINGFIELD, Mo.--BUSINESS WIRE--

QPS Holdings, LLC announced today that their Springfield campus, QPS Missouri, has launched a new Cell Therapy business unit. The unit’s first achievement is the opening of a new Leukopak collection and blood product processing center. This facility is designed to meet the exponentially growing demand for blood products to support cell and gene therapy work. QPS is a full service CRO that’s dedicated to supporting drug development from conceptualization through to commercial launch. This facility is providing critical raw materials for the research and development of cell therapies but will soon be supporting clinical and commercial cell therapy companies and patients. In addition, this new facility will support the local economy by providing stipends to blood product donors.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241113328476/en/

The new QPS Cell Therapy Unit in Springfield, Missouri is a Leukopak collection and blood product processing center designed to meet the exponentially growing demand for blood products to support cell and gene therapy work. (Photo: Business Wire)

The new QPS Cell Therapy Unit in Springfield, Missouri is a Leukopak collection and blood product processing center designed to meet the exponentially growing demand for blood products to support cell and gene therapy work. (Photo: Business Wire)

To build out the facility and ensure the success of this new venture, QPS has hired Tia Hexom, PhD, (Senior Director of Cell Therapy Services and Manufacturing). With over a decade of experience in the cell therapy field, Hexom is excited to be building cell therapy capabilities in the Midwestern United States.

QPS Missouri is a division of QPS Holdings LLC, a global Clinical Research Organization (CRO) that conducts studies on behalf of pharmaceutical and biotech companies for the development of new and existing pharmaceutical products. This new Leukopak and Cell Therapy products donation and processing center will be housed in the same building as the new, state-of-the-art Screening and Recruitment Center that opened in July 2022, located at 2025 W. Sunshine Street, Springfield, MO. Study participants and blood product donors are paid a stipend for their participation in these Clinical Research activities. These stipends benefit the study participants and donors and, therefore, the local economy.

“Our participants and donors are a key part of the success of QPS in Springfield, Missouri and they continue to make a difference by helping advance drug development research,” states Brendon Bourg, Vice President, Early Phase Clinical/Head of Administration QPS Missouri. “To have the opportunity and ability to provide this type of supplemental income to our local community, while providing a valuable service to our pharmaceutical and biotech clients is something we (QPS) are honored to be a part of.”

Located in Springfield, QPS Missouri has been conducting clinical research studies for over 30 years, with the help of more than 50,000 study participants. In addition to the new Cell Therapy facilities, the Springfield campus houses five independent clinics with more than 240 beds, a pharmacy with a retention area, local and central CAP/CLIA safety lab, a clinical trial kit processing area, and a 2,500 square foot negative pressure room.

QPS has always been on the front line of clinical research in all areas of pharmaceutical and biotech drug development. Since opening its doors in Springfield in 1994, QPS Missouri has conducted more than 2,000 Phase I FDA-regulated studies and paid over $50 million to local participants and donors.

ABOUT QPS HOLDINGS, LLC

QPS is a global, full-service, GLP/GCP-compliant contract research organization (CRO) delivering the highest grade of discovery, bioanalysis, preclinical and clinical drug development services. Since 1995, QPS has grown from a small bioanalysis shop into a full-service CRO with 1,100+ employees in the US, Europe, and Asia. Today, QPS offers expanded pharmaceutical contract R&D services with special expertise in pharmacology, DMPK, toxicology, bioanalysis, translational medicine, cell therapy products (such as Leukopaks and PBMCs), clinical trials, and clinical research services. An award-winning leader focused on bioanalysis and clinical trials, QPS is known for proven quality standards, technical expertise, a flexible approach to research, client satisfaction, turnkey laboratories, Phase I clinical facilities, and multi-site clinical research services. Through continual enhancements in capacities and resources, QPS stands tall in its commitment to delivering superior quality, skilled performance, and trusted service to its valued customers. For more information, visit www.qps.com or email [email protected].


Contact details:

Gabrielle Pastore, QPS Marketing
Phone: 302-287-7821
Email: [email protected]
Website: www.qps.com

Media

More from this category

  • Medical Health Aged Care
  • 18/12/2025
  • 22:11
BeOne Medicines Ltd.

BeOne Medicines Granted U.S. FDA Fast Track Designation for BGB-B2033 as Treatment for Hepatocellular Carcinoma

BGB-B2033 is a bispecific antibody directed at GPC3 and 4-1BB; key targets in the most common liver cancer FDA Fast Track Designation reflects the…

  • Contains:
  • Medical Health Aged Care
  • 18/12/2025
  • 19:11
Takeda Pharmaceutical Company Limited

Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment

Pivotal Phase 3 studies of once-daily oral zasocitinib met all primary and ranked secondary endpoints in patients with moderate-to-severe plaque psoriasis More than half…

  • Contains:
  • Medical Health Aged Care
  • 18/12/2025
  • 12:24
La Trobe University

Cell death discovery could aid cancer treatments

LaTrobe researchers have made a groundbreaking discovery about the way dying cells are cleared from our bodies, which could have important impacts on recovery from diseases including cancer infection and inflammatory diseases. Traditionally, it was believed dying cells were broken into smaller pieces by the cell’s own internal machinery, enabling the pieces to be more easily removed from the body. However the study, led by scientists at the La Trobe Institute for Molecular Science and Research Centre for Extracellular Vesicles found that the process of dying cell fragmentation is actually assisted by neighbouring cells. Published in Science Advances, the study…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.